Research is being conducted to leverage the genetics of psychiatric disorders to identify potential drug targets and compounds. This work involves using genetic data to prioritize targets and compounds for various conditions, including schizophrenia and opiate use disorder. The approach also appears to be applied to other diseases, such as type 2 diabetes and major depressive disorder, to improve understanding and potential treatment options.